![](https://static.scientificamerican.com/dam/m/334c6c3a4ef22a6a/original/E82BNY_WEB.jpg?w=1200)
FDA’s Rejection of MDMA Psychotherapy for Trauma Draws Criticism from Psychedelic Experts
On August 9 a drugmaker announced that the U.S. Food and Drug Administration had informed the company that it would not approve the psychedelic MDMA for use in psychotherapy for post-traumatic stress disorder (PTSD). The FDA asked Lykos Therapeutics, which …